Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chindex Announces Higher $23/Share Takeover Offer

publication date: Apr 14, 2014
Chindex, the US-based operator of China hospitals and clinics, received a new takeover offer of $23 per share from an undisclosed entity. The offer is an 18% improvement on the $19.50 bid, made in February, from a group comprised of Fosun Pharma, TPG (a US private equity group) and Roberta Lipson, CEO of Chindex. A definitive agreement has been negotiated with the entity behind the latest offer, which is all-cash and not subject to any financing contingencies. More details....

Stock Symbols: (NSDQ: CHDX) (SHA: 600196; HK: 2196)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here